Having demonstrated the capacity of CART cells co-secreting IL6 and IL1 blockers and their safety in mouse model, we initiated a clinical investigation of the safety and efficacy of CART-aIL6/IL1RA for targeting CD19 or BCMA, with 18 patients enrolled, including ALL, CLL, lymphoma and multiple myeloma (MM) as summarized in Table 1. Here, TNFRSF17 is linked to plasma cell myeloma.